Arrayjet business expansion translates into job creation and fuels next generation bio-printing technology
- Posted: 05/05/17
We are delighted to announce that our recent funding round led by Archangel Investors closed at £650,000. This will drive the expansion of Arrayjet Advance in-house consultancy services, increase our global commercial resources and bring new products to market. We have recently started the process of designing and developing its next generation bio-printing technological solutions with a new product scheduled for launch in 2018.
- Posted: 28/03/17
Arrayjet’s steady growth strategy in North America has been boosted by a contract win for its instrumentation business with The New York Bioscience Cluster, a global pioneer in biomedical research. The Bioscience Cluster facility is located in The Bronx.
- Posted: 23/12/16
Arrayjet is delighted to share it's growing presence in Asia-Pacific by securing a $300,000 deal with Shanghai-based Abmart, a biological and life science technology specialist which is working to industrialise the production of monoclonal antibodies for academic research institutes, biotechnology companies and pharmaceutical laboratories across the globe.
- Posted: 04/07/16
Arrayjet, is proud to announce that we have secured a $400,000AUD contract with one of Australia’s flagship biomedical research institutes, housing some of the
country’s most renowned research groups in developing the next generation of
drugs and vaccines to fight diseases of global significance and impact.